Informal two-component combination label
Wolverine is a community name for using BPC-157 and TB-500 together. No controlled or registered study of the verified combination was located. FDA summarized one confounded adverse-event report naming both materials, while a tiny knee report used BPC-157 plus unverified thymosin beta-4 material.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
The human combination record is limited to one confounded adverse-event report and a four-person subgroup using unverified thymosin-beta-4 material.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
No controlled trial verifies TB-500 exposure, isolates a combination effect, measures pharmacokinetics, or establishes adverse-event incidence.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The report described recurrent skin and gingival darkening, but product identity, purity, sterility, amounts, concomitant substances, causation, and incidence were not established. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
Wolverine is a community name for using BPC-157 and TB-500 together. No controlled or registered study of the verified combination was located. FDA summarized one confounded adverse-event report naming both materials, while a tiny knee report used BPC-157 plus unverified thymosin beta-4 material.
Includes PubMed and ClinicalTrials.gov search audits through July 25, 2026, FDA's 2026 component reviews and adverse-event summary, and current BPC-157 and TB-500 component records.
What the evidence says
For the combination, one confounded FDA adverse-event report and a four-person subgroup exposed to BPC-157 plus material described as thymosin beta-4. Neither establishes benefit, safety, or verified TB-500 exposure in a controlled study.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Verified product identity, ratio, compatibility, stability, pharmacokinetics, interactions, immunogenicity, dose-response, adverse-event incidence, safety, and clinical effects of the actual two-component mixture.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
A July 2026 PubMed audit found no controlled study administering verified BPC-157 and the seven-amino-acid TB-500 fragment together.
A July 2026 ClinicalTrials.gov audit found no registered trial of the verified BPC-157/TB-500 combination.
FDA summarized diffuse hyperpigmentation and gingival darkening that reportedly recurred when the combination was restarted.
No results are posted. The registration cannot establish benefit for BPC-157 or for the Wolverine combination.
The two participants had no reported adverse effects or meaningful short-term laboratory changes during the pilot.
Administration and handling
No human trial or approved label establishes a Wolverine route, dose, schedule, ratio, or reconstitution process. A voluntary adverse-event report and an uncontrolled knee case series describe exposure; they do not establish an appropriate procedure. Ingredient-specific research and withdrawn nomination details cannot be combined into guidance.
No published compatibility or stability study was located for BPC-157 and TB-500 mixed together. Individual material observations cannot establish blend stability, sterility, precipitation risk, aggregation risk, container compatibility, or beyond-use time.
Primary-source ledger
2026-07-25
2026-07-25
2026-07-23
2026-07-21
2026-02-27 · NCT07437547
2026-01-01
2025-09-01 · PMID 40131143
2024-03-15 · PMID 38382158 · DOI 10.1016/j.jchromb.2024.124033
2021-07-01 · PMID 34324435